Patent · US Active

Polymorphic forms and co-crystals of a c-Met inhibitor

US9981988B2 · kind B2 · utility

0Cited by

4References

3Claims

0Family size

Assignee

AMGEN INC. · US

Inventors

David Bauer · Sudbury, US
Matthew Bio · Boston, US
Melanie Cooke · Arlington, US
Katrina Woodin Copeland · Sudbury, US
Matthew Peterson · Hopkinton, US
Michele Potashman · Cambridge, US
Roman Shimanovich · Watertown, US
Helming Tan · Thousand Oaks, US

Key dates

Filing date	Oct 14, 2016
Grant date	May 29, 2018
Priority date	—
Expiry date	Oct 14, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07B2200/13
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.